Data from other pregnancy cohorts, comparing birth outcomes among IBD patients treated with vedolizumab, TNF inhibitors, and biological therapy, have shown that excluding patients with active disease, the risks of adverse outcomes, congenital abnormalities, and number of miscarriages were similar among all treatment groups.34 Results from the PIANO registry19 suggest biologic treatment during pregnancy in women with IBD was not found to be associated with increased maternal or newborn AEs, consistent with the findings in this IBD pregnancy cohort. Here, TNF is linked to inflammatory bowel disease.